Marked Interindividual Variability in the Response to Selective Inhibitors of Cyclooxygenase-2

FitzGerald, 2001, The coxibs, selective inhibitors of cyclooxygenase-2, N Engl J Med, 345, 433, 10.1056/NEJM200108093450607 Bombardier, 2000, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group, N Engl J Med, 343, 1520, 10.1056/NEJM200011233432103 Schnitzer, 2004, Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications, Lancet, 364, 665, 10.1016/S0140-6736(04)16893-1 Steinbach, 2000, The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis, N Engl J Med, 342, 1946, 10.1056/NEJM200006293422603 Ott, 2003, Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery, J Thorac Cardiovasc Surg, 125, 1481, 10.1016/S0022-5223(03)00125-9 Solomon, 2005, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention, N Engl J Med, 352, 1071, 10.1056/NEJMoa050405 Bresalier, 2005, Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, N Engl J Med, 352, 1092, 10.1056/NEJMoa050493 Nussmeier, 2005, Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery, N Engl J Med, 352, 1081, 10.1056/NEJMoa050330 Tacconelli, 2002, The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity, Curr Med Res Opin, 18, 503, 10.1185/030079902125001335 McAdam, 1999, Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2, Proc Natl Acad Sci U S A, 96, 272, 10.1073/pnas.96.1.272 Catella-Lawson, 1999, Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids, J Pharmacol Exp Ther, 289, 735 Cheng, 2002, Role of prostacyclin in the cardiovascular response to thromboxane A2, Science, 296, 539, 10.1126/science.1068711 Qi, 2002, Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II, J Clin Invest, 110, 61, 10.1172/JCI0214752 Kobayashi, 2004, Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice, J Clin Invest, 114, 784, 10.1172/JCI200421446 FitzGerald, 2003, COX-2 and beyond, Nat Rev Drug Discov, 2, 879, 10.1038/nrd1225 FitzGerald, 2004, Coxibs and cardiovascular disease, N Engl J Med, 351, 1709, 10.1056/NEJMp048288 Furberg, 2005, Parecoxib, valdecoxib, and cardiovascular risk, Circulation, 111, 249, 10.1161/01.CIR.0000155081.76164.17 Israel, 2004, Use of regularly scheduled albuterol treatment in asthma, Lancet, 364, 1505, 10.1016/S0140-6736(04)17273-5 Wood, 2001, Racial differences in the response to drugs—pointers to genetic differences, N Engl J Med, 344, 1394, 10.1056/NEJM200105033441811 Catella-Lawson, 2001, Cyclooxygenase inhibitors and the antiplatelet effects of aspirin, N Engl J Med, 345, 1809, 10.1056/NEJMoa003199 Patrignani, 1982, Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects, J Clin Invest, 69, 1366, 10.1172/JCI110576 Panara, 1999, Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects, J Pharmacol Exp Ther, 290, 276 FitzGerald, 1983, Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease, Circulation, 67, 1174, 10.1161/01.CIR.67.6.1174 Catella, 1987, Paired analysis of urinary thromboxane B2 metabolites in humans, Thromb Res, 47, 647, 10.1016/0049-3848(87)90103-4 Wiltshire, 2003, Genome-wide single-nucleotide polymorphism analysis defines haplotype patterns in mouse, Proc Natl Acad Sci U S A, 100, 3380, 10.1073/pnas.0130101100 Yan, 2004, Estimating equations for association structures, Stat Med, 23, 859, 10.1002/sim.1650 Spiegelhalter, 1999 Patrono, 2001, Cyclooxygenase-selective inhibition of prostanoid formation, J Clin Invest, 108, 7, 10.1172/JCI200113418 Thomas, 1998, Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2, J Clin Invest, 102, 1994, 10.1172/JCI5116 Francois, 2004, Role for thromboxane receptors in angiotensin-II-induced hypertension, Hypertension, 43, 364, 10.1161/01.HYP.0000112225.27560.24 Cayatte, 2000, The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice, Arterioscler Thromb Vasc Biol, 20, 1724, 10.1161/01.ATV.20.7.1724 Egan, 2004, COX-2 derived prostacyclin confers atheroprotection on female mice, Science, 360, 1954, 10.1126/science.1103333 Wang, 2005, The role of prostaglandins and other eicosanoids in the gastrointestinal tract, Gastroenterology, 128, 1445, 10.1053/j.gastro.2004.09.080 Malmstrom, 1999, Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain, Clin Ther, 21, 1653, 10.1016/S0149-2918(99)80045-9 Morrison, 2000, The optimal analgesic dose of rofecoxib, J Am Dent Assoc, 131, 1729, 10.14219/jada.archive.2000.0119 Markiewicz, 1979, Time dependent changes in the pharmacokinetics of aspirin, Int J Clin Pharmacol Biopharm, 17, 409 Clench, 1981, Circadian changes in the bioavailability and effects of indomethacin in healthy subjects, Eur J Clin Pharmacol, 20, 359, 10.1007/BF00615406 1998, 1 Hogenesch, 2003, Circadian transcriptional output in the SCN and liver of the mouse, Novartis Foundation Symposium, 253, 171, 10.1002/0470090839.ch13 Drazen, 2000, Heterogeneity of therapeutic responses in asthma, Br Med Bull, 56, 1054, 10.1258/0007142001903535 Chladek, 2002, Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis, Br J Clin Pharmacol, 54, 147, 10.1046/j.1365-2125.2002.01621.x Stahle, 2004, Efavirenz plasma concentrations in HIV-infected patients, Ther Drug Monit, 26, 267, 10.1097/00007691-200406000-00008 Ulrich, 2002, Cyclooxygenase 1 polymorphisms in African-American and Caucasian populations, Hum Mutat, 20, 409, 10.1002/humu.9080 Papafili, 2002, Common promoter variant in cyclooxygenase-2 represses gene expression, Arterioscler Thromb Vasc Biol, 22, 1631, 10.1161/01.ATV.0000030340.80207.C5 Halushka, 2003, Genetic variation in cyclooxygenase 1, Clin Pharmacol Ther, 73, 122, 10.1067/mcp.2003.1 Tang, 2000, Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor, J Pharmacol Exp Ther, 293, 453 Lee, 2002, Cytochrome P450 2C9 polymorphisms, Pharmacogenetics, 12, 251, 10.1097/00008571-200204000-00010 Scordo, 2002, Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance, Clin Pharmacol Ther, 72, 702, 10.1067/mcp.2002.129321